Meta-analysis Of Treatment Of Diabetic Kidney Disease With Huangkui Capsule And ARB Or ACEI

Objectives In this study,relevant literatures were sorted out through Meta analysis,to evaluate the efficacy of huangkui capsule combined with ARB or ACEI in the treatment of diabetic kidney disease,to provide Evidence-based medicine for the treatment of diabetic kidney disease with huangkui capsule combined with ARB or ACEIMaterial and method:Designing a paper retrieval strategy,identifying keywords,and searching Chinese and English databases,including China Biomedical Literature Database(CBM),VIP Chinese Science and Technology Periodical Database(VIP),China National Knowledge Infrastructure(CNKI),Wanfang Medical net database,Pubmed,Cochrane library,search time limits January 2009 to December 2019,formulated inclusion and exclusion criteria,screend the literatures by two researchers,determined the final inclusion of the literatures.the basic characteristics and data of the literatures were extracted by Excel,the RevMan5.3 software provided by the Cochrane assistance network was used for analysis,and meta-analysis,sensitivity analysis,publication bias and other systematic evaluations were performed on the included literaturesResults:1.A total of 14 randomized controlled clinical trials were included,14 of which were in Chinese.A total of 1299 patients were included,including 650 in the experimental group and 649 in the control group2.The experimental group of the 14 literatures were treated with hu angkui capsule combined with ARB or ACEI.The control group of the 14 literatures were all treated with ARB or ACEI(Of these,11 literatu res were treated with valsartan alone,1 article was treated with irbesar tan alone,benazepril hydrochloride alone was used in 2 literatures)3.There were 14 included articles,the course of treatment was 4 weeks in one of the literatures,the course of treatment of 11 literatures was 8 weeks,the treatment course of 1 literature was 12 weeks,the course of treatment was 16 weeks in one of the literatures4.meta-analysis results showed that:① overall effect:the combined effect RR=1.29,95%CI(1.20,1.38),Z test:Z=7.28,P<0.00001.② BUN:the combined effect MD=-0.14,95%CI(-0.31,0.04),Z test:Z=1.53,P=0.13.③Scr:the combined effect SMD=-0.21,95%CI(-0.33,-0.09),Z test:Z=3.35,P=0.0008④24 hours urine protein quantification:the combined effect SMD=-0.45,95%CI(-0.61,-0.29),Z test:Z=5.56,P<0.00001.⑤UAER:the combined effect SMD=-1.45,95%CI(-1.73,-1.16),Z test:Z=9.78,P<0.00001.⑥TG:the combined effect SMD=-0.76,95%CI(-1.10,-0.43),Z test:Z=4.46,P<0.00001.⑦TC:the combined effect SMD=-1.85,95%CI(-2.79,-0.92),Z test:Z=3.88,P=0.00015.Safety aspect:Adverse reactions of drugs were reported in 9 litera tures,while adverse reactions of drugs were not mentioned in 5 literatu res.Since adverse reactions reported in the literatures did not affect ou tcome indicators,no analysis was conductedConclusion:Huangkui capsule combined with ARB or ACEI in the treatment of diabetic kidney disease in the overall effect,TC,24 hours urine protein quantification,UAER,Scr and TG are superior to ARB or ACEI alone.